THE COST EFFECTIVENESS OF BAOFUKANG VERSUS XINFUNING IN THE TREATMENT OF HPV INFECTION
Author(s)
SUN L, LU Y, Duan X, Chen Y
Shenyang Pharmaceutical University, shenyang, China
Presentation Documents
OBJECTIVES: Human Papilloma Virus (HPV) is a common venereal disease virus, and 5 percent of the cancer is caused by persistent infection of HPV. HPV infection is unable to be eradicated, and continuous high risk HPV infection will increase the disease risk of cervical cancer and other diseases. Baofukang(1.74g/grain) and Xinfuning(800 thousand IU/grain) are widely used in treatment of HPV infection, while the former is Chinese patent medicine. This study aims to evaluate the cost-effectiveness of Baofukang and Xinfuning in the treatment of HPV infection, providing references for reasonable clinical prescription, pricing drugs and the cognition product value. METHODS: A decision-analytic model was developed to estimate the cost-effectiveness of Baofukang and Xinfuning from the perspective of the whole society. In the model, outcome on effectiveness was based on quantitative synthetic of Meta analysis. And cost data was mainly based on the published data and in combination with China’s practical situation. The single factor sensitivity analysis was made based on the change of effectiveness and price. RESULTS: The effective rate of Baofukang when the treatment time was 48 days was 61.89%, and the effective rate was 63.05% when treatment time was 42 days, while Xinfuning’s effective rate was 46.58% when treatment time was 30 days. The total cost were $101.43,$95.58,$129.07, respectively. CONCLUSIONS: Results of the model indicate that Baofukang appears to be the most cost-effective. Total costs of Baofukang under different treatment time were lower than the Xinfuning group, while Baofukang hold a higher effective rate. The availability of more high-quality clinical data would allow a better adaptation of the model . Future research could be focused on this.
Conference/Value in Health Info
2016-05, ISPOR 2016, Washington DC, USA
Value in Health, Vol. 19, No. 3 (May 2016)
Code
PIH29
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Reproductive and Sexual Health